Honokiol, magnolol and its monoacetyl derivative show strong anti-fungal effect on Fusarium isolates of clinical relevance

Safa Oufensou1, Barbara Scherm1, Giovanna Pani1, Virgilio Balmas1,*, Davide Fabbri2, Maria Antonietta Dettori2, Paola Carta2, Ismael Malbrán3, Quirico Migheli1, Giovanna Delogu2*

1 Dipartimento di Agraria, Sezione di Patologia Vegetale ed Entomologia and Unità di Ricerca Istituto Nazionale di Biostrutture e Biosistemi, Università degli Studi di Sassari, Viale Italia, Sassari, Italy, 2 Istituto CNR di Chimica Biomolecolare, Traversa La Crucca, Sassari, Italy, 3 Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)—Centro de Investigaciones de Fitopatología (CIDEFI-CIC-UNLP), Facultad de Ciencias Agrarias y Forestales, Universidad Nacional de La Plata, La Plata–Buenos Aires, Argentina

* balmas@uniss.it(VB);, giovanna.delogu@icb.cnr.it(GD)

Abstract

The antifungal activity of magnolol and honokiol, two naturally occurring hydroxylated biphenyls, and of their synthetic derivatives was evaluated on a collection of representative isolates of Fusarium oxysporum, F. solani and F. verticillioides of clinical and ecological concern. The tested compounds were proposed as a ‘natural’ alternative to conventional fungicides, even though a larger range of concentrations (5–400 μg/ml) was applied. The activity of magnolol and honokiol was compared with that of terbinafine (0.1–10 μg/ml), and fluconazole (1–50 μg/ml), two fungicides widely used in treating fungal infections on humans. Magnolol showed similar fungicidal activity compared to fluconazole, whereas honokiol was more effective in inhibiting mycelium growth compared to this fungicide on all tested clinical Fusarium spp. isolates. Compared to terbinafine, honokiol showed similar antifungal activity when tested on clinical F. solani isolates, whereas magnolol was less effective at all selected concentrations (5–400 μg/ml). The different position of the phenol-OH group, as well as its protection, explain different in vitro activities between magnolol, honokiol, and their derivatives. Furthermore, magnolol showed mycelium dry weight reduction at a concentration of 0.5 mM when tested on a set of agricultural isolates of Fusaria, leading to complete inhibition of some of them. Magnolol and honokiol are proposed as efficient and safe candidates for treating clinically relevant Fusaria.

Introduction

Natural occurring polyphenols are a great source of biologically active compounds beneficial to human and animal health [1]. Magnolol (1, 5,5’-diallyl-2,2’-dihydroxybiphenyl) and honokiol (2, 5,5’-diallyl-2,4’-dihydroxybiphenyl) are two hydroxylated biphenyl-type neolignans
and represent the main components of the bark of *Magnolia officinalis*, *M. obovata*, *M. grandiflora* and *M. dealbata* [2]. These compounds have long been important substances in traditional Chinese and Ayurvedic medicine due to their wide biological activities [3]. Magnolol 1 and honokiol 2 are chemically stable and commercially available in large amounts at a reasonable price. In the bark of *M. officinalis*, magnolol 1 and honokiol 2 were identified in ratios of approximately 4:1; honokiol 2 ranges from 17 to 19 mg/g of extract, whereas magnolol 1 is present in the roots at a concentration of 87–96 mg/g. Although the main source of magnolol 1 and honokiol 2 are species of *Magnolia* growing in China, Japan and South Korea, both compounds are also found in other species of this genus present in Mexico. In Asia, these compounds are used in modern clinical practice, while in the United States and Europe are considered cosmetic additives [3].

The unique pharmacophore structure of magnolol 1 and honokiol 2, formed by two hydroxylated aromatic rings bridged by a single C-C bond representative of the hydroxylated biphenyl structure, has a crucial role in their biological activity [4]. This structural feature allows the activation of a large number of interactions with the surface of proteins [5].

The spectrum of inflammatory diseases to which they provide relief is broad, including allergic rhinitis, influenza and diarrhoea, but also myocardial infarction and anxiety episodes [3, 6]. The biological activity of magnolol 1 and honokiol 2 is likely to depend on the hydroxyl group located at the biphenyl moiety and the allyl chain in para (magnolol 1 and honokiol 2) and in ortho (honokiol 2) position to the phenol-OH group, which adds further features to these molecules, such as anti-oxidative, anti-proliferative, anti-fungal, anti-tumoral, anti-HIV and neuroprotective activities [3, 7–10]. This wide array of positive properties makes the two molecules potential candidates in the search for new drugs effective at treating various inflammatory diseases, such as osteoarthritis or acne, but also for prophylaxis of biofilm-forming streptococci causing caries [11].

In hospitals, multi-resistant bacterial and poorly treatable fungal infections have become a serious problem in recent years [12, 13]. Invasive filamentous fungal infections have a growing incidence in immune-compromised subjects such as AIDS patients, recipients of kidney transplants or people suffering from haematological diseases [14]. Among them, *Fusarium* spp. are common human pathogenic fungi implicated in invasive mycoses and infections. Fusariosis is, after aspergillosis, the second most common mould infection in humans [15, 16]. In healthy humans, *Fusarium* spp., particularly *F. verticillioides*, *F. solani* and *F. oxysporum*, are frequently reported as the cause of dermatological affections such as onychomycoses and paronychia, but they may also induce keratitis episodes, mainly as a consequence of contaminated lens solutions [17]. *F. solani* and *F. oxysporum* represent the major opportunistic human pathogenic filamentous fungi, being responsible for approximately two-thirds of the reported fusarioses. In immune-compromised patients, *Fusarium* infections lead to disseminated fusarioses, which are frequently fatal. In addition to an often-late diagnosis of *Fusarium* spp. infection, currently administrated antifungal drugs are poorly effective due to the high degree of resistance shown by representatives of this genus [15].

*Fusarium* spp. are present in several ecosystems including agricultural soil, with relevant impact on cereal crops [18, 19]. Among other species, *F. graminearum* and *F. culmorum* are the main pathogens causing *Fusarium* head blight (FHB) and foot and root rot (FRR) on wheat and other small grains, where they induce yield losses, poor grain quality and contamination with type-B trichothecene mycotoxins [20]. Fungicides bearing an azole unit are widely used for plant and human protection against *Fusarium* spp., as they are generally inexpensive, have a broad-spectrum of action and long stability. However, in recent years, large-scale deployment of azole fungicides in agriculture has been considered as a potential cause of the increasing resistance phenomena found also in human pathogenic fungi [21]. Despite different
plant extracts are effective against human fusarioses [22], the scarce availability of natural sources from which large amounts of them can be obtained at stable concentrations hamper their application.

In our previous studies devoted to the search of effective sustainable fungicides in agriculture, we observed antifungal activity of magnolol 1 against F. graminearum and F. culmorum, both in vitro [23] and in silico [24]. Magnolol 1 manifested the highest anti-fungal activity among a wide range of natural occurring phenols, with fungal growth inhibition at concentrations as low as 0.125 mM. Furthermore, magnolol 1 and honokiol 2 are generally recognised as harmless for humans and animals [25]. Cytotoxicity (IC50) against normal human lymphocytes was set at 38.6 μM for magnolol 1 and 16.1 μM for honokiol 2 [26]. Both compounds are metabolized by extrahepatic and hepatic pathways, producing mainly glucuronic derivatives. Moreover, magnolol 1 is not phytotoxic at concentrations up to 1.5 mM [23]. Considering that many antifungal drugs exert toxic effects on human cells, these characteristics make magnolol 1 and honokiol 2 excellent candidates as sustainable and commercially available fungicides against human and animal pathogens. However, the poor aqueous solubility of magnolol 1 and honokiol 2, common in natural polyphenols, has hampered their broad clinical application. In order to overcome this issue, encapsulation of honokiol has been assessed [27] and synthetic derivatives were prepared [28]. Nevertheless, derivatives and improved formulations of these compounds are often limited by toxicity and drug interaction, hence preventing their use in medical practice. The pro-drug approach [29] represents a versatile strategy to improve the bioactivity of such molecules by transformation of the hydroxyl groups of magnolol 1 and honokiol 2 in an ester group with a mono- and diacetyl functional group or in an acetal group with a glucose unit, respectively. These ester or acetal groups would undergo in vivo biotransformation through chemical or enzymatic cleavage, thus favouring the delivery of the active compound with a higher yield.

Aims of the present work were: 1) to evaluate the inhibitory activity of magnolol 1 and honokiol 2 over a collection of Fusarium spp. isolates of clinical and phytopathogenic interest, and 2) to develop derivatives of magnolol 1 and honokiol 2 with improved water solubility and equal inhibitory activity compared to the parental compounds. In a preliminary experiment, the spectrum of activity of magnolol 1 was tested against representative isolates of Fusarium species of relevant human concern or of phytopathogenic interest. Subsequently, magnolol 1, honokiol 2, and their derivatives (compounds 3–8, Fig 1) were tested for their anti-fungal activity and specificity towards human and nosocomial isolates. The activity of these compounds was compared with that of terbinafine and fluconazole, two common fungicides. To our knowledge, this is the first time that magnolol 1 and honokiol 2 are assayed over a collection of Fusarium spp. relevant to both plant and human health.

**Material and methods**

**Strains and culture**

In a preliminary screening, thirty-two Fusarium spp. isolates from the collection of the University of Sassari (PVS-Fu) sampled from soil (10 isolates), diseased plants (9 isolates), and from human specimen (13 isolates) and water tap (1 isolate) in different Italian hospitals were tested against magnolol 1 (Table 1).

Subsequently, a selection of F. oxysporum, F. solani and F. verticillioides isolates from the PVS-Fu collection, collected from human samples, water tap, and basin sink in different Italian hospitals and identified morphologically and molecularly by analysis of the elongation factor gene sequence (TEF-1α) was tested (Table 2).
Magnolol 1 and honokiol 2 were purchased from Chemos GmbH, Germany. Magnolol mono acetate 3, magnolol diacetate 4, honokiol 2-mono acetate 5, honokiol 4'-mono acetate 6 and honokiol diacetate 7 (Fig 1) were prepared as previously described [8]. All compounds were synthesized with the same purity obtained before and judged by $^1$H-NMR spectral determination (in Supporting Information S1 Text). Magnolol mono glucopyranoside 8, β-anomer, was prepared under chemical and sustainable conditions starting from magnolol-2-O-(2',3',4',6'-tetra acetyl)-β-D-glucopyranoside. Structure of 8 was confirmed by comparison with spectroscopic data present in literature of an identical β-anomer achieved under enzymatic conditions (S1 Text in Supporting information).

**Lipophilicity estimation**

Lipophilicity was estimated using the logarithm of the partition coefficient for n-octanol/water (log P), implemented in the ChemBioDraw Ultra 13.0 software.

**Evaluation of antifungal activity in Vogel’s medium**

In a preliminary assay, the antifungal activity of magnolol 1 at 0.5 mM was evaluated according to Pani et al. [23] on thirty-two isolates of *Fusarium* spp. (Table 1). Vogel’s medium was amended with 0.5 mM of magnolol 1 and sonicated for one hour at room temperature. Three replicates of $10^4$ conidia in 8 ml of Vogel’s/magnolol 1 medium for each strain were cultured at 25˚C in the dark without shaking. After 14 days, mycelia were recovered, filtered and dried at 85˚C for 48 h. Inhibition was expressed as dry weight percentage of the untreated test.

**Evaluation of antifungal activity in potato dextrose agar (PDA)**

In a second test, the antifungal activity of magnolol 1, honokiol 2 and their derivatives 3–8 (Fig 1) was assessed by comparison with terbinafine and fluconazole, two common fungicides of clinical use, on a selection of *F. oxysporum*, *F. solani* and *F. verticillioides* isolates collected...
from different Italian hospitals (Table 2). Concentration of compounds 1–4 and 8 ranged from 5 to 400 μg/ml, while concentrations between 5–100 μg/ml were used for compounds 5–7. The concentrations of terbinafine and fluconazole ranged from 0.1–10 μg/ml and 1–50 μg/ml, respectively. Antifungal activity was measured after three days of growth on potato dextrose agar (PDA) medium at 25˚C in the dark in the presence of the different concentrations (μg/ml) of each compound and expressed as the colony diameter in percentage relative to control. Concentrations of conventional fungicides were selected according to clinical dosage and standard experimental procedures [30]. PDA was amended with each inhibitor suspension previously sonicated for an hour at room temperature. Conidial suspensions of each strain

Table 1. List of the set of 32 Fusarium spp. isolates obtained from soil (10 isolates), diseased plants or grain (9 isolates), water tap and human specimen (13 isolates) in different hospitals tested in the preliminary screening.

| Species        | NRRL n. a | PVS-Fu n. b | Diagnosis c | Isolate source | Date   | Origin     |
|----------------|------------|-------------|-------------|----------------|--------|------------|
| F. chlamydosporum | -          | 4           | FHB         | durum wheat    | 1994   | Voghera    |
| F. crookwellense  | -          | 6           | FRR         | bread wheat    | 1989   | Perugia    |
| F. crookwellense  | -          | 406         | FHB         | durum wheat    | 2008   | Sassari    |
| F. guttiforme     | 53131      | 864         | Paronychia  | finger         | 2007   | Milano     |
| F. langsethiae d  | -          | 341         | FHB         | wheat          | -      | -          |
| F. pseudograminearum | -       | 7           | FRR         | durum wheat    | 1992   | Foggia     |
| F. solani        | 46443      | 93          | Dermatomycosis | foot     | 2004   | Milano     |
| F. solani        | 46440      | 97          | Onychomycosis | finger   | 2005   | Milano     |
| F. solani        | -          | 100         | Onychomycosis | toe      | 2006   | Milano     |
| F. solani        | 52832      | 95          | Onychomycosis | toe     | 2007   | Milano     |
| F. solani        | -          | 105         | Onychomycosis | toe     | 2010   | Milano     |
| F. solani        | 44937      | 107         | -           | soil          | 2007   | Sassari    |
| F. solani        | 46672      | 108         | -           | soil          | 2007   | Cagliari   |
| F. solani        | 44924      | 109         | -           | soil          | 2007   | Cagliari   |
| F. solani        | 46492      | 110         | -           | soil          | 2007   | Nuoro      |
| F. solani        | 46676      | 111         | -           | soil          | 2007   | Cagliari   |
| F. subglutinans  | -          | 10          | -           | soil          | 1998   | Bari       |
| F. subglutinans  | 22034      | 187         | -           | maize         | -      | Iran       |
| F. verticillioides | -         | 400         | -           | maize         | 2001   | Bergamo    |
| F. verticillioides | 53119     | 112         | Sepsis      | leukaemia-blood | 2007 | Ancona     |
| F. verticillioides | 53125     | 113         | Sepsis      | kidney transplant-blood | 2007 | Novara     |
| F. verticillioides | 44894     | 88          | Paronychia  | finger        | 2006   | Milano     |
| F. oxysporum     | -          | 222         | -           | -             |        | -          |
| F. oxysporum     | 46489      | 123         | -           | soil          | 2007   | Nuoro      |
| F. oxysporum     | 46480      | 124         | -           | soil          | 2007   | Nuoro      |
| F. oxysporum     | 46603      | 89          | Onychomycosis | toe   | 2004   | Milano     |
| F. oxysporum     | 46595      | 126         | Onychomycosis | toe    | 2007   | Milano     |
| F. oxysporum     | 52682      | 127         | Onychomycosis | toe    | 2007   | Milano     |
| F. oxysporum     | 44899      | 128         | Onychomycosis | toe    | 2006   | Milano     |
| F. oxysporum     | -          | 516         | -           | water tap     | 2013   | Sassari    |
| F. equiseti      | 46660      | 146         | -           | soil          | 2007   | Cagliari   |
| F. equiseti      | 44916      | 147         | -           | soil          | 2007   | Cagliari   |

a NRRL Collection number of Agricultural Research Service (ARS).
b PVS-Fu n. Collection number of Dipartimento di Agraria, Sezione Patologia Vegetale ed Entomologia, Sassari, Italy.
c FRR Fusarium Foot Root Rot; FHB Fusarium Head Blight.
d Strains 01–113 kindly provided by Prof. Y. Mattila.

https://doi.org/10.1371/journal.pone.0221249.t001
were prepared by growing the fungi on carboxymethyl cellulose (CMC) medium [31] for 7 days at 25 °C and 170 rpm in the dark. Cultures were filtered, the spores were collected by centrifugation and the concentration was adjusted to ~ 10^6 colony-forming units (CFU)/ml in sterile water. Ten microliters of the conidial suspension of each strain were plated on the amended PDA. Three replicates were prepared for each inhibitor and concentration.

**Measurement of Minimal inhibitory concentration (MIC)**

The inhibitory activity of each compound was expressed as Minimal Inhibitory Concentration (MIC) and represents the lowest concentration of active ingredient (μg/ml) that is sufficient to inhibit fungal growth.

**Measurement of Lethal Dose 50 (LD₅₀)**

The Lethal Dose 50 of each compound was calculated as the concentration of active ingredient (μg/ml) able to reduce by 50% the growth of the fungus in vitro.

**Statistical analysis**

Data on mycelium weight (mg of dry weight per Petri plate) and mycelium growth (mm per Petri plate), obtained from separate experiments, were expressed as percentage of the relative control treatment and pooled to perform statistical analyses. To compare the activities of different concentrations of each of the selected compounds, a one-way analysis of variance (ANOVA) was performed, followed by multiple comparisons by Tukey HSD test at P = 0.01 using Minitab for Windows, release 17. Prior to performing the ANOVA, normality of

---

**Table 2. List of 15 Fusarium spp. isolates of clinical relevance tested in the present study.**

| n. | Species       | NRRL n. | PVS-Fu n. | Diagnosis               | Isolate source | Date | Origin | Hospital |
|----|---------------|----------|-----------|-------------------------|----------------|------|--------|----------|
| 1  | *F. verticillioides* | -        | 604       | Dead patient            | Hospital       | 2013 | Nuoro  | NU       |
| 2  | *F. verticillioides* | 53129    | 86        | Pneumonia               | Broncho alveolar lavage | 2007 | Varese | V        |
| 3  | *F. verticillioides* | 46599    | 87        | Onychomycosis           | Toe            | 2007 | Milan  | M-1      |
| 4  | *F. verticillioides* | 53126    | 84        | Chronic sinusitis       | Maxillary sinus pus | 2007 | Novara | N        |
| 5  | *F. verticillioides* | 53122    | 83        | Sepsis in leukemia      | Blood          | 2007 | Milan  | M-3      |
| 6  | *F. verticillioides* | 44894    | 88        | Paronychia              | Finger         | 2006 | Milan  | M        |
| 7  | *F. solani*     | 53120    | 94        | Sepsis                  | Blood          | 2007 | Milan  | M-3      |
| 8  | *F. solani*     | 44903    | 96        | Onychomycosis           | Toe            | 2006 | Milan  | M-1      |
| 9  | *F. solani*     | -        | 502       | -                       | Sink           | 2013 | Sassari| SS       |
| 10 | *F. solani*     | 46443    | 93        | Dermatomycosis          | Foot           | 2004 | Milan  | M-1      |
| 11 | *F. oxysporum*  | 46603    | 89        | Onychomycosis           | Toe            | 2004 | Milan  | M-1      |
| 12 | *F. oxysporum*  | -        | 516       | -                       | Water tap      | 2013 | Sassari| SS       |
| 13 | *F. oxysporum*  | 53121    | 92        | Soft tissue Kaposi’s sarcoma | Pus            | 2007 | Milan  | M-2      |
| 14 | *F. oxysporum*  | 46600    | 90        | Dermatomycosis          | Foot           | 2007 | Milan  | M-1      |
| 15 | *F. oxysporum*  | 46606    | 91        | Onychomycosis           | Toe            | 2005 | Milan  | M-1      |

*a* NRRL n. Collection number of Agricultural Research Service (ARS).

*b* PVS-Fu n. Collection number of Dipartimento di Agraria, Sezione Patologia Vegetale ed Entomologia, Sassari, Italy.

*c* Locations of eight Italian hospitals sampled listed by city: A, Ancona (Marche region, central Italy); M-1, Sesto San Giovanni Hospital, Milan; M-2, hospital 2, Milan; M-3, hospital 3, Milan; M-4, hospital 4, Milan; V, Varese (Lombardy region, northern Italy); N, Novara (Piedmont region, northern Italy); NU, Nuoro (Sardinia, Italy island); T, Torino (Piedmont region, northern Italy); SS, Sassari (Sardinia, Italy island).

*d* Isolates in bold were included in the preliminary screening.

https://doi.org/10.1371/journal.pone.0221249.t002
residuals was verified by the Shapiro-Wilk test, whereas assumption of homoscedasticity was checked by the Levene test.

Results

Antifungal activity of magnolol 1 on a collection of representative isolates of *Fusarium* spp.

The inhibitory effect of magnolol 1 on the dry weight of thirty-two *Fusarium* strains tested in Vogel’s medium is reported on Table 3.

Table 3. Mycelium dry weight reduction of 32 *Fusarium* spp. isolates obtained from soil (10 isolates), diseased plants or grain (9 isolates), a water tap and human specimen (13 isolates) in different hospitals treated with mag- nolol at 0.5 mM.

| Species           | PVS-Fu n. | Dry weight (% of control) |
|-------------------|-----------|---------------------------|
| *F. chlamydosporum* | 4         | 30.6 ± 11.4               |
| *F. crookwellense*  | 6         | 56.5 ± 15.9               |
| *F. crookwellense*  | 406       | 56.0 ± 10.0               |
| *F. guttiforme*     | 864       | 0 ± 0                     |
| *F. langsethiae*    | 341       | 18.3 ± 2.4                |
| *F. pseudograminearum* | 7   | 28.5 ± 10.8               |
| *F. solani*         | 93        | 43.6 ± 5.5                |
| *F. solani*         | 97        | 0 ± 0                     |
| *F. solani*         | 100       | 66.6 ± 29.1               |
| *F. solani*         | 95        | 64.9 ± 7.3                |
| *F. solani*         | 105       | 49.0 ± 18.2               |
| *F. solani*         | 107       | 43.3 ± 12.6               |
| *F. solani*         | 108       | 34.3 ± 18.2               |
| *F. solani*         | 109       | 0 ± 0                     |
| *F. solani*         | 110       | 25.7 ± 8.1                |
| *F. solani*         | 111       | 34.3 ± 18.2               |
| *F. subglutinans*   | 10        | 8.7 ± 2.1                 |
| *F. subglutinans*   | 187       | 4.1 ± 0.6                 |
| *F. verticilloides* | 400       | 45.1 ± 22.3               |
| *F. verticilloides* | 112       | 8.4 ± 5.0                 |
| *F. verticilloides* | 113       | 5.2 ± 2.0                 |
| *F. verticilloides* | 88        | 43.1 ± 10.9               |
| *F. oxysporum*      | 222       | 60.3 ± 23.9               |
| *F. oxysporum*      | 123       | 42.9 ± 8.4                |
| *F. oxysporum*      | 124       | 39.0 ± 3.9                |
| *F. oxysporum*      | 89        | 22.3 ± 2.6                |
| *F. oxysporum*      | 126       | 24.2 ± 3.6                |
| *F. oxysporum*      | 127       | 80.0 ± 17.3               |
| *F. oxysporum*      | 128       | 49.7 ± 14.7               |
| *F. oxysporum*      | 516       | 67.1 ± 12.1               |
| *F. equiseti*       | 146       | 21.5 ± 2.4                |
| *F. equiseti*       | 147       | 0 ± 0                     |

*PVS-Fu n. Collection number of Dipartimento di Agraria, Sezione Patologia Vegetale ed Entomologia, Sassari, Italy.

https://doi.org/10.1371/journal.pone.0221249.t003
Except for *F. crookwellense* 6, *F. crookwellense* 406, *F. oxysporum* 127, *F. oxysporum* 222, *F. oxysporum* 516, *F. solani* 95, and *F. solani* 100, the remaining 25 Fusarium isolates underwent a mycelium dry weight reduction greater than 50% when exposed to magnolol 1 at 0.5 mM (Table 3).

Complete or almost complete inhibition was observed in eight isolates, four of them belonging to clinical Fusarium collected from human specimen (PVS-Fu, 864; 95; 112; 113, Table 2 and Table 3). Magnolol 1 at 0.5 mM was very effective on *F. guttiforme* 864 cultured from a paronychial infection and against *F. verticillioides* 112 and *F. verticillioides* 113, collected from pathological human blood, leading to complete inhibition of mycelium growth. Complete inhibition was also observed for *F. solani* 97, whereas more than 50% reduction of mycelium dry weight was obtained for *F. solani* 105 and *F. solani* 93. Similarly, onycomycosis-causing *F. oxysporum* 89 and *F. oxysporum* 126 were inhibited by over 75%, whereas *F. oxysporum* 127 was inhibited only by 20%.

### Selection and activity of two conventional fungicides targeted at *Fusarium* isolates of clinical relevance

Terbinafine and fluconazole, two conventional fungicides, were assayed over a range of 0.1–10 μg/ml and 1–50 μg/ml, respectively, on a set of *F. verticillioides*, *F. solani* and *F. oxysporum* isolates from human samples and clinical environment (Table 2). With different levels of intensity, *F. verticillioides* isolates were the most sensitive, whereas *F. solani* isolates showed the lowest sensitivity towards both fungicides (Fig A and Fig B in Supporting Information). In particular, *F. verticillioides* isolates were highly sensitive to terbinafine, with MICs ranging from 1 to 5 μg/ml and LD$_{50}$ between 0.1 and 1 μg/ml (Table 4).

At 25 μg/ml, fluconazole was able to completely inhibit the vegetative growth of all *F. verticillioides* isolates, whereas almost 60% mycelium growth inhibition was observed for *F. solani* 502 and for all *F. oxysporum* isolates. The mycelium growth of *F. solani* 94 and *F. solani* 96 was not affected by fluconazole even at the highest concentration of 50 μg/ml. Even at lower concentrations (5–10 μg/ml), terbinafine showed more effective antifungal activity (growth

### Table 4. LD$_{50}$ and MIC values (in μg/ml) of terbinafine, fluconazole, magnolol 1 and honokiol 2 tested against *Fusarium* spp.

|                  | Terbinafine | Fluconazole | Magnolol 1 | Honokiol 2 |
|------------------|-------------|-------------|------------|------------|
|                  | LD$_{50}$   | MIC         | LD$_{50}$  | MIC        | LD$_{50}$ | MIC       | LD$_{50}$ |
| F. verticillioides 604 | 0.1–0.5     | 1–5         | 10–25      | 10–25      | 10–50     | >400       | 5–10     |
| F. verticillioides 86 | 0.5–1       | 1–5         | 10–25      | 10–25      | 50        | >400       | 5–10     |
| F. verticillioides 87 | 0.5–1       | 1–5         | 10–25      | 10–25      | 5–10      | >400       | 5        |
| F. verticillioides 84 | 0.1–0.5     | 1–5         | 10–25      | 10–25      | 50–100    | >400       | 5–10     |
| F. verticillioides 83 | 0.1–0.5     | 1–5         | 10–25      | 10–25      | 10–50     | >400       | 5–10     |
| F. verticillioides 88 | 0.1–0.5     | 1–5         | 10–25      | 10–25      | 5–10      | >400       | 5–10     |
| F. solani 94       | 1–5         | >10         | >50        | >50        | 100       | >400       | 5–10     |
| F. solani 96       | 1–5         | >10         | >50        | >50        | 10–50     | >400       | 5–10     |
| F. solani 502      | 1–5         | >10         | >50        | >50        | 5–10      | >400       | 5–10     |
| F. solani 93       | 1–5         | >10         | >50        | >50        | 10–50     | >400       | 5–10     |
| F. oxysporum 89    | 1–5         | 5–10        | >50        | >50        | 5–10      | >400       | 5–10     |
| F. oxysporum 516   | 1–5         | 5–10        | >50        | >50        | 5–10      | >400       | 5–10     |
| F. oxysporum 92    | 1–5         | 1–5         | >50        | >50        | 5–10      | >400       | 5–10     |
| F. oxysporum 90    | 1–5         | 5–10        | >50        | >50        | 5–10      | >400       | 5–10     |
| F. oxysporum 91    | 1–5         | 5–10        | >50        | >50        | 5–10      | >400       | <5       |

https://doi.org/10.1371/journal.pone.0221249.t004
inhibition being > 50%) than fluconazole in all isolates belonging to the three *Fusarium* species complexes (Fig A and Fig B in Supporting Information).

**Antifungal activity of magnolol 1, honokiol 2 and their derivatives 3–8**

Isolates belonging to *F. oxysporum* were more sensitive to magnolol 1 compared to the other species (Table 4). Magnolol 1 affected all isolates belonging to the three species complexes with a mycelium growth inhibition >50% at 100 μg/ml; the trend was not significantly different at 200 μg/ml and for *F. verticillioides* 604, *F. solani* 502, *F. oxysporum* 89, *F. oxysporum* 90 and *F. oxysporum* 91 even at 400 μg/ml (Fig C in Supporting Information). MIC of magnolol 1 was >400 μg/ml for all the tested *Fusarium* isolates (Table 4).

Over a concentration range of 10–100 μg/ml, honokiol 2 completely inhibited mycelium growth in all 15 fungal strains investigated (Fig D in Supporting Information). More than 50% mycelium growth inhibition was observed in all *Fusarium* spp. when honokiol 2 was amended at 10 μg/ml. In *F. verticillioides* 84, a fungus responsible for chronic sinusitis, honokiol 2 showed strong antifungal activity with MIC between 5 and 10 μg/ml (Table 4). Honokiol 2 was more effective than magnolol 1 at inhibiting *F. solani*, with MIC ranging from 10 to 100 μg/ml, except for *F. solani* 93, whose MIC was comprised between 5 and 10 μg/ml. Besides *F. oxysporum* 91, antifungal activity of magnolol 1 was comparable to that of honokiol 2 in *F. oxysporum* isolates, with a LD₅₀ ranging from 5 to 10 μg/ml. However, magnolol 1 could not completely inhibit fungal growth at the tested concentrations, whereas honokiol 1 did over a range of 10–100 μg/ml.

A mono protection of the phenol-OH with an acetyl group in magnolol 1 (compound 3) had a higher effect on MIC values in *F. verticillioides* 83, *F. verticillioides* 86, *F. verticillioides* 88 and *F. solani* 93 (Table 5 and Fig E in Supporting Information).

At 400 μg/ml, almost complete growth inhibition was observed in *F. oxysporum* 89, *F. solani* 93, *F. verticillioides* 83, *F. verticillioides* 84, *F. verticillioides* 86, and *F. verticillioides* 88. At 100 μg/ml, magnolol mono acetate 3 inhibited by 50% the mycelium growth of all the tested strains (Fig E in Supporting Information). Conversely, magnolol mono glucopyranoside 8 was not effective at concentration up to 400 μg/ml on all the *Fusarium* species complexes (Fig K in Supporting Information).

Honokiol mono acetate 5 and 6 proved less effective than the parent compound, with LD₅₀ and MIC values higher than those displayed by honokiol 2 (Table 5). At 100 μg/ml, except for *F. solani* 94, *F. solani* 96 and *F. solani* 93, honokiol 2-mono acetate 5 and honokiol 4’-mono acetate 6 inhibited by 50% the vegetative growth of all *Fusarium* isolates (Fig G and Fig H in Supporting Information). The colony growth of *F. verticillioides* 87, *F. verticillioides* 88 and *F. oxysporum* 90 was inhibited by 80% in the presence of honokiol 2-mono acetate 5 at 100 μg/ml. Honokiol diacetate 7 was less effective against all the *Fusarium* species complexes (Table 5 and Fig I in Supporting Information). Complete protection of both phenol-OH groups in magnolol 1 and honokiol 2 determined a reduction of their efficacy (Table 5 and Fig I in Supporting Information).

Compounds 1–7 showed comparable lipophilicity estimated by LogP between 4.99 and 5.03, while LogP 2.36 was calculated for magnolol mono glucopyranoside 8.

**Comparison of antifungal activity of compounds 1–8 with the conventional fungicides**

When the activity of magnolol 1, honokiol 2 and their derivatives 3–8 was compared with that of terbinafine and fluconazole, a different trend of efficacy was observed (Table 4 and Table 5 and Figs A-K in Supporting Information).
Table 5. LD$_{50}$ and MIC values (in μg/ml) of magnolol and honokiol derivatives 3–8 tested against *Fusarium* spp.

|                | Magnolol monoacetate 3 | Magnolol diacetate 4 | Magnolol monoglucopyranoside 8 | Honokiol 2-monooacetate 5 | Honokiol 4’-monooacetate 6 | Honokiol diacetate 7 |
|----------------|------------------------|----------------------|-------------------------------|---------------------------|---------------------------|----------------------|
|                | LD$_{50}$ | MIC  | LD$_{50}$ | MIC  | LD$_{50}$ | MIC  | LD$_{50}$ | MIC  | LD$_{50}$ | MIC  | LD$_{50}$ | MIC  |
| *F. verticilloides* 604 | 10–50     | >400  | >400     | >400  | >400     | >400  | 50–100   | >100  | >100     | >100  | >100     | >100  |
| *F. verticilloides* 86   | 10–50     | 200–400 | >400     | >400  | >400     | >400  | 50–100   | >100  | 25–50    | >100  | >100     | >100  |
| *F. verticilloides* 87   | 10–50     | >400  | >400     | >400  | >400     | >400  | 50–100   | >100  | 25–50    | >100  | >100     | >100  |
| *F. verticilloides* 84   | 10–50     | >400  | >400     | >400  | >400     | >400  | 50–100   | >100  | >100     | >100  | >100     | >100  |
| *F. verticilloides* 83   | 10–50     | 200–400 | >400     | >400  | >400     | >400  | 25–50    | >100  | >100     | >100  | >100     | >100  |
| *F. verticilloides* 88   | 10–50     | 100–400 | >400     | >400  | >400     | >400  | 25–50    | >100  | >100     | >100  | >100     | >100  |
| *F. solani* 94          | 50–100    | >400  | >400     | >400  | >400     | >400  | >100     | >100  | >100     | >100  | >100     | >100  |
| *F. solani* 96          | 100–200   | >400  | >400     | >400  | >400     | >400  | >100     | >100  | >100     | >100  | >100     | >100  |
| *F. solani* 502         | 10–50     | >400  | >400     | >400  | >400     | >400  | 50–100   | >100  | >100     | >100  | >100     | >100  |
| *F. solani* 93          | 50–100    | 200–400 | >400     | >400  | >400     | >400  | >100     | >100  | >100     | >100  | >100     | >100  |
| *F. oxysporum* 89       | 10–50     | >400  | >400     | >400  | >400     | >400  | 25–50    | >100  | >100     | >100  | >100     | >100  |
| *F. oxysporum* 516      | 10–50     | >400  | >400     | >400  | >400     | >400  | 50–100   | >100  | >100     | >100  | >100     | >100  |
| *F. oxysporum* 92       | 10–50     | >400  | >400     | >400  | >400     | >400  | 25–50    | >100  | >100     | >100  | >100     | >100  |
| *F. oxysporum* 90       | 10–50     | >400  | >400     | >400  | >400     | >400  | 25–50    | >100  | >100     | >100  | >100     | >100  |
| *F. oxysporum* 91       | 10–50     | >400  | >400     | >400  | >400     | >400  | 25–50    | >100  | >100     | >100  | >100     | >100  |

With the exception of *F. solani* 94, LD$_{50}$ of magnolol 1 for both *F. solani* and *F. oxysporum* species complexes was lower than that of fluconazole. Magnolol 1 showed better or similar inhibitory activity than fluconazole at 5 μg/ml, whereas honokiol 2 showed a higher inhibition of mycelium growth compared to the conventional fungicide for all clinical *Fusarium* species complexes (Figs B-D in Supporting Information). Conversely to terbinafine and fluconazole, honokiol 2 showed comparable inhibitory activity against all three species complexes (Fig D in Supporting Information). Table A in Supporting Information reports a comparison of μg/ml and molarity for all investigated compounds with that of fluconazole and terbinafine. Furthermore, the growth inhibition data of terbinafine, fluconazole, magnolol 1 and honokiol 2 were collected in four graphics where concentrations in μg/ml were converted to molarity (Fig 2A, 2B, 2C and 2D). In Fig 2A the summary effect of terbinafine, fluconazole, magnolol 1 and honokiol 2 on *F. oxysporum*, *F. solani* and *F. verticillioides* is shown. Terbinafine and honokiol 2 were both able to inhibit mycelium growth effectively. Nevertheless, terbinafine, at the tested clinical dosages, could not completely inhibit fungal growth as honokiol 2 did on all *Fusarium* isolates over a range of 37.5–375 μM (10–100 μg/ml). The effect of magnolol 1 and fluconazole is superimposable over a range of concentrations, roughly between 19 and 160 μM, though magnolol 1 was more effective as vegetative growth inhibitor.

Comparable LD$_{50}$ was observed on *F. oxysporum* 91 collected from onychomycosis, when treated with terbinafine (1–5 μg/ml, 3.4–17 μM) and honokiol 2 (<5 μg/ml, < 18.8 μM) (Table 4). At clinical dosages, fluconazole was not effective against this set of *F. oxysporum* isolates (Fig 2B), whereas magnolol 1 and honokiol 2 were more effective, the latter being able to provide complete fungal growth inhibition at 0.375 mM (100 μg/ml).

Except for *F. solani* isolates, terbinafine was able to inhibit mycelium growth over a range between 3.4–34.3 μM (10–100 μg/ml), i.e., smaller by roughly one order of magnitude compared to honokiol 2 (Fig 2C). Over a range of 5–10 μg/ml (18.8–37.5 μM), honokiol 2 was as effective as terbinafine (10 μg/ml, 34 μM) in inhibiting the colony growth (MIC) of *F. solani* 93, isolated from foot dermatomycosis (Table 3). Moreover, at 10 μg/ml, honokiol 2 (37.5 μM) had a similar effect compared to that of terbinafine (34 μM) in inhibiting *F. solani* 502 isolated
from a hospital basin sink and, to a lesser extent, *F. oxysporum* 516 collected from a hospital water tap (Table 4 and Fig A and Fig D in Supporting Information). Terbinafine and fluconazole were able to inhibit fungal growth of *F. verticillioides* with MIC value $<5\,\mu g/ml$ and $<25\,\mu g/ml$, respectively (Table 4), while honokiol 2 followed the same trend as terbinafine, providing a complete fungal growth inhibition at $<100\,\mu g/ml$.

**Discussion**

The objective of this work was to propose ‘natural’ alternatives to the use of conventional fungicides, even if this approach required the use of higher concentrations of the identified compounds. The compounds we tested, namely magnolol 1 and honokiol 2, are commercially available in large amounts and have been used in modern clinical practice in Eastern Asia, while in the United States and Europe are considered cosmetic additives.

In a preliminary screening, the selection of *Fusarium* spp. from agricultural and human sources provided a general information of the potential antifungal activity of magnolol 1 towards these fungi, including ubiquitous representatives of the *F. solani* and *F. oxysporum* species complexes. With different ranges of intensity, magnolol 1 was able to control all *F. oxysporum* and *F. solani* isolates sampled from human specimen. Magnolol 1 also proved a potential candidate to control *F. subglutinans* and, to a lesser extent, *F. verticillioides* 400, two species able to infect corn. Data reported in Table 3 highlight a different sensitivity of isolates within the same species complex, regardless of their origin.

Subsequently, this study was carried out on *Fusarium* spp. of clinical interest, aiming at testing the antifungal activity of magnolol 1, honokiol 2 and their derivatives 3–8 as sustainable alternatives to current clinical drug treatments, which suffer from frequent emergence of
resistant pathogen populations. Two commercial fungicides with different mode of action, i.e. terbinafine and fluconazole, were selected in order to compare their antifungal activity with that of compounds 1–8 against all clinical Fusarium spp. isolates. Terbinafine, a tertiary allylamine and one of the most effective antifungal drugs used in human therapy, inhibits the ergosterol biosynthesis by acting on the squalene epoxidation and is widely used for the treatment of nail infections [32]. Fluconazole, an inhibitor of the lanosterol 14α-demethylase, belongs to the azole SBI class I, whose activity is weaker than that of terbinafine. Although acquired resistance against fluconazole was observed in Fusarium spp. of agricultural interest, the fungicide is still being used in the clinical treatment of these fungi [33, 34]. Concentrations of terbinafine and fluconazole were selected according to literature [30].

Magnolol 1, honokiol 2 and their derivatives 3–8 were tested at concentrations ranging from twenty-five-fold lower and, roughly three-fold higher than those used to amend Vogel’s medium in the preliminary assay. This concentration range allowed us to compare the species diversity and the antifungal susceptibility profile of the clinical isolates with all tested. Over an acceptable range of variability, percentage of growth inhibition of compounds 1–89 and 1–91 observed in Vogel’s assay with magnolol 1 was comparable to that observed on PDA, suggesting that growth inhibition is independent from the cultural medium. In our screening, magnolol 1 and its structural isomer, honokiol 2, showed effective antifungal activity. These compounds may prove useful in antimicrobial drug development, based on their recognised multitarget bioactivities, market availability and almost safe metabolic profile in human body [25, 26]. Moreover, the capacity of magnolol 1 and honokiol 2 to act on multiple cell targets can be the key to control infection by resistant fungi which do not respond to conventional therapies.

When the concentrations applied were analysed in terms of molarity, a clearer comparison of the antifungal activities of terbinafine, fluconazole, magnolol 1 and honokiol 2 was obtained. Even though different ranges of molarity were taken into account, a very similar trend in the activities of terbinafine and honokiol 2 was observed. In the case of F. oxysporum 91, honokiol 2 was very effective, thereby appearing as a promising antifungal agent in the treatment of onychomycoses. Interestingly, the antifungal activity of honokiol 2 towards F. solani 93, isolated from foot dermatomycosis, and, to a lesser extent, against F. solani 502, isolated from hospital basin sink, was comparable to that exerted by terbinafine. Due to the acceptable metabolic profile of honokiol 2 taken in oral dosage, these results suggest a potential application of this compound in washing water contaminated by F. oxysporum and in the sanitation of sinks.

A pro-drug approach [29] was applied as a versatile strategy to improve the bioactivity of these compounds by transformation of the hydroxyl groups of magnolol 1 and honokiol 2 in a mono- and di-acetyl ester, respectively, and, in the case of magnolol 1, in a mono glucosyl acetal 8. The antifungal activity of honokiol 2 dropped when one of the phenol-OH was protected with an acetyl group (i.e. in compounds 5 and 6). The effect was less remarkable between honokiol 4’-mono acetate 6 and honokiol 2-mono acetate 5, further highlighting the importance of both phenol-OH groups in the activity of honokiol 2. On the contrary, magnolol mono acetate 3 showed higher inhibitory activity than the corresponding parental compound, whereas the bioactivity dropped when phenol-OH groups were protected with two acetyl groups.

Due to the presence of a glucosyl unit, magnolol mono glucopyranoside 8 was more hydrophilic compared to compounds 1–7. Although a free phenol-OH group is present in the structure of this compound, it is possible that its poor antifungal activity is a result of its failure to reach its target in the fungal cell through the lipophilic membrane.

Magnolol 1 and honokiol 2 are structural isomers, but the different position of one phenol-OH group confers distinct conformations and electronic effects and, as a result, a different reactivity (e.g., antioxidant activity) [7]. A C2'-symmetry axis in magnolol 1 allows only one
monoester isomer, whereas two distinct isomers can be produced after monoesterification of honokiol 2. Phenol-OH groups in magnolol 1 have different acidity due to the formation of an intramolecular H-bond between the two phenol-OH. On the contrary, in honokiol 2, the large dihedral angle and the distance of the two phenol-OH groups reduce the conjugation effect. These features reflect the different activity that monoesters and diesters of magnolol 1 and honokiol 2 have displayed during in vitro assays. According to the position of the two phenol-OH groups in the biphenyl structure, a different mechanism of action between magnolol 1 and honokiol 2 might take place when these compounds interact with fungi.

Several modes of action of magnolol 1 and honokiol 2 were described towards fungi [35–37]. Magnolol 1 interacts with ergosterol present in the cell membrane, inducing a partial disruption of the structure, but its mechanism of action is likely to differ from that of other inhibitors of sterol biosynthesis as it has proven effective also on fluconazole-resistant Candida spp. isolates [38]. Cell wall components such as β-1,3-glucans were proposed as potential target of magnolol, similarly to fungicides of the echinocandin family [39].

It is reasonable to hypothesize that other mechanisms underlay the antifungal activity of magnolol 1 and honokiol 2 that may justify a differential action towards the three investigated Fusarium species complexes. Recently, the role of honokiol 2 as activator of mitochondrial ROS by mitochondrial dysfunction and depolarisation of mitochondrial membrane potential in C. albicans was highlighted [40]. Moreover, honokiol 2 is able to hinder the high content of pro-oxidant iron ions in fungi by sequestering the ion [41]. Having different targets and multiple mechanisms of action, it is likely that honokiol 2 acts more effectively than magnolol 1 on selected fungal targets. In fact, candidates that are able to induce dysfunction of mitochondrial membrane and alteration of iron homeostasis represent the new pharmacological leads currently under development [42]. The scarce toxicity of magnolol 1 upon dermal and oral administration, which is even lower than that of honokiol 2 [25, 26], opens new straightforward clinical applications for this compound.

In conclusion, our findings suggest that magnolol 1, honokiol 2 and magnolol acetate 3 may represent promising alternatives for the treatment of fungal infections on both plants and humans: they share a different mode of action compared to conventional antifungal drugs, whose clinical application is jeopardized by the onset of resistance phenomena in fungal populations. The low toxicity of magnolol 1 and honokiol 2, their low cost and their efficacy against both yeast and filamentous fungi prompt further investigation on other fungal pathogens relevant in human or plant clinics and, to a large extent, on fungal pathogens of ecological concern.

Supporting information

S1 Text. Supplementary material and methods, synthesis and references. Comparison of μg/ml and molarity (μM or mM) for compounds 3–8 with that of fluconazole and terbinafine (Table A). Raw datasets of the effect of compounds 1–8, terbinafine and fluconazole on mycelium growth of Fusarium oxysporum, Fusarium verticillioides and Fusarium solani (Table B). Antifungal activity of terbinafine (Fig A). Antifungal activity of fluconazole (Fig B). Antifungal activity of compound 1 (Fig C). Antifungal activity of compound 2 (Fig D). Antifungal activity of compound 3 (Fig E). Antifungal activity of compound 4 (Fig F). Antifungal activity of compound 5 (Fig G). Antifungal activity of compound 6 (Fig H). Antifungal activity of compound 7 (Fig I). Antifungal activity of compound 8 (Fig K). Photos of mycelium growth of five Fusarium oxysporum isolates in the presence of magnolol 1 at 5 and 400 μg/ml in comparison with control (Fig L).
Photos of mycelium growth of six *Fusarium verticillioides* isolates in the presence of magnolol 1 at 5 and 400 μg/ml in comparison with control (Fig M).

Photos of mycelium growth of four *Fusarium solani* isolates in the presence of magnolol 1 at 5 and 400 μg/ml in comparison with control (Fig N).

**Acknowledgments**

This work has been supported by CNR-CONICET Bilateral project 2016–2018, by Fondazione Sardegna—Annualità 2016, and by Regione Sardegna L.R. 7/2017—Annualità 2016.

S.O. acknowledges financial support from SIPCAM Italia S.p.A.

We thank Dr. Silvana Sanna and Dr. Henry Harak for the clinical isolates kindly provided.

**Author Contributions**

**Conceptualization:** Virgilio Balmas, Quirico Migheli, Giovanna Delogu.

**Data curation:** Safa Oufensou, Davide Fabbri, Maria Antonietta Dettori, Paola Carta.

**Formal analysis:** Barbara Scherm, Giovanna Pani, Davide Fabbri, Maria Antonietta Dettori, Paola Carta.

**Funding acquisition:** Safa Oufensou, Maria Antonietta Dettori, Ismael Malbrán, Quirico Migheli, Giovanna Delogu.

**Investigation:** Safa Oufensou, Barbara Scherm, Giovanna Pani.

**Methodology:** Safa Oufensou, Barbara Scherm, Giovanna Pani, Davide Fabbri, Maria Antonietta Dettori, Paola Carta.

**Project administration:** Ismael Malbrán, Quirico Migheli, Giovanna Delogu.

**Resources:** Ismael Malbrán, Quirico Migheli, Giovanna Delogu.

**Software:** Safa Oufensou.

**Supervision:** Virgilio Balmas, Quirico Migheli, Giovanna Delogu.

**Validation:** Safa Oufensou.

**Visualization:** Safa Oufensou.

**Writing – original draft:** Virgilio Balmas, Giovanna Delogu.

**Writing – review & editing:** Virgilio Balmas, Ismael Malbrán, Quirico Migheli, Giovanna Delogu.

**References**

1. Pandey KB and Rizvi SI. Current understanding of dietary polyphenols and their role in health and disease. Curr Nutr & Food Sci. 2009; 5: 249–263.

2. Yahara S, Nishiyori T, Kohda A, Nohara T, Nishioka I. Isolation and characterization of phenolic compounds from *Magnoliae* cortex produced in Cina. Chem Pharm Bull. 1991; 39: 2014–2036.

3. Lee YJ, Lee YM, Lee CK, Jung JK, Han SB, Hong JT. Therapeutic applications of compounds in the *Magnolia* family. Pharmacol Ther. 2011; 130: 157–76.

4. Bringmann G, Gulder T, Gulder TAM, Breunung M. Atroposelective total synthesis of axially chiral biaryl natural products. Chem Rev. 2011; 111: 563–539.

5. Hajduk PJ, Bures M, Praestagaard J, Fesik SW. Privileged molecules for protein binding identified from NMR base screening. J Med Chem. 2000; 43: 3443–3447.
6. Chen Y-H, Huang P-H, Lin F-Y, Chen W-C, Chen Y-L, Yin W-H, et al. Magnolol: a multifunctional compound isolated from the Chinese medicine plant Magnolia officinalis. Eur J Integr Med. 2011; 3: e317–324.

7. Amorati R, Zotta J, Baschieri A, Valgimigli L. Antioxidant activity of magnolol and honokiol: kinetic and mechanistic investigations of their reaction with peroxyl radicals. J Org Chem. 2015; 60: 10651–10659.

8. Maioli M, Basoli V, Carta P, Fabbri D, Dettori MA, Cruciani S, et al. Synthesis of magnolol and honokiol derivatives and their effect against hepatocarcinoma cells. PLoS ONE 2018; 13: e0192178. https://doi.org/10.1371/journal.pone.0192178 PMID: 29415009

9. Greenberg M, Dodds M, Tian M. Naturally occurring phenolic antibacterial compounds show effectiveness against oral bacteria by a quantitative structure-activity relationship study. J Agric Food Chem. 2008; 56: 11511–11516.

10. Hoi CP, Ho YP, Baum L, Chow AHL. Neuroprotective effect of honokiol and magnolol, compounds from Magnolia officinalis, on beta-amyloid-induced toxicity in PC12 cells. Phytotherapy Res. 2010; 24: 1538–1542.

11. Chen YJ, Tsai KS, Chan DC, Lan KC, Chen CF, Yang RS, Liu SH. Honokiol, a low molecular weight natural product, prevents inflammatory response and cartilage matrix degradation in human osteoarthritis chondrocytes. J Orthop Res. 2011; 32: 573–580.

12. Debourgogne A, Dorin J, Machouart M. Emerging infections due to filamentous fungi in humans and animals: only the tip of the iceberg? Environ Microbiol Rep. 2016; 8: 332–342.

13. Migheli Q, Balmas V, Harak H, Sanna S, Scherm B, Aoki T, et al. Molecular phylogenetic diversity of dermatologic and other human pathogenic fusarial isolates from hospitals in northern and central Italy. J Clin Microbiol. 2010; 48: 1076–1084.

14. Nucci M and Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev. 2007; 20: 695–704.

15. Al-Hatmi AMS, Bonifaz A, Ranque S, Sybren de Hoog G, Verweij PE, Meis JF. Current antifungal treatment of fusariosis. Int J Antimicrob Agents 2018; 51: 326–332.

16. Guarro J. Fusariosis, a complex infection caused by a high diversity of fungal species refractory to treatment. Eur J Clin Microbiol Infect. Dis. 2013; 32: 1491–1500.

17. Ahearn DG, Zhang S, Stulting DR, Schwam BL, Simmons B, Ward MA et al. Fusarium keratitis and contact lens wear: facts and speculations. Med Mycol. 2008; 46: 397–310.

18. Goswami RS and Kistler C. Heading for disaster: Fusarium graminearum on cereal crops. Mol Plant Pathol. 2004; 5: 515–525.

19. Scherm B, Balmas V, Spanu F, Pani G, Delogu G, Pasquali M, et al. Fusarium culmorum: causal agent of foot and root rot and head blight on wheat. Mol Plant Pathol. 2014; 14: 323–41.

20. Pasquali M, Bayer M, Logrieco A, Audenaert K, Balmas V, Basler R, et al. A European database of Fusarium graminearum and F. culmorum trichothecene genotypes. Frontiers Microbiol. 2016; 7: 406.

21. Revie NM, Iyer KR, Robbins N, Cowen LE. Antifungal drug resistance: evolution, mechanisms and impact. Curr Opin Microbiol. 2018; 45: 70–76.

22. Zabka M, Pavela R, Gabriela-Slezakova L. Promising antifungal effect of some Euro-Asianic plants against dangerous pathogenic and toxigenic fungi. J Sci Food Agric. 2011; 91: 492–497.

23. Pani G, Scherm B, Azara E, Balmas V, Jahanshiri Z, Carta P, et al. Natural and natural-like phenolic inhibitors of type B-trichothecene in vitro production by the wheat (Triticum sp.) pathogen Fusarium culmorum. J Agric Food Chem. 2014; 62: 4969–4978.

24. Pani G, Dessi A, Dallocchio R, Scherm B, Azara E, Delogu G, et al. Natural phenolic inhibitors of trichothecene biosynthesis by the wheat fungal pathogen Fusarium culmorum: a computational insight into the structure-activity relationship. PLoS ONE 2016; 11: e0157316. https://doi.org/10.1371/journal.pone.0157316 PMID: 27294666

25. Sarrica A, Kirka N, Romeo M, Salmona M, Diomede L. Safety and toxicology of magnolol and honokiol. Planta Med. 2018; 84: 1151–1164. https://doi.org/10.1055/a-0642-1966 PMID: 29925102

26. Ambland F, Govindarajan B, Lefkove B, Rapp KL, Detorio M, Arbiser JL, et al. Synthesis, cytotoxicity, and antiviral activities of new neolignans related to honokiol and magnolol. Bioorg Med Chem Lett. 2007; 17: 4428–4431.

27. Zhang Y, Chen T, Yuan P, Tian R, Hu W, Tang Y, Jia Y, et al. Encapsulation of honokiol into self-assembled pectin nanoparticles for drug delivery to HepG2 cells. Carbohydr Polim. 2015; 133: 31–38.

28. Yang C, Zhi X, Xu H. Advances on semisynthesis, total synthesis, and structure-activity relationship of honokiol and magnolol derivatives. Mini Rev Med Chem. 2016; 16: 404–426. PMID: 26586125
29. Hartmann Jornada D, dos Santos Fernandes GF, Eidy Chiba D, Ferreira de Melo TR, dos Santos JL, Chung MC. The prodrug approach: a successful tool for improving drug solubility. Molecules 2016; 21: 42. https://doi.org/10.3390/molecules21010042 PMID: 26729077

30. Bueno JG, Martinez C, Zapata B, Sanclemente G, Gallego M, Mesa AC. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis. Clin Exp Dermatol. 2010; 35: 658–663.

31. Cappellini RA and Peterson JL. Macroconidium formation in submerged cultures by a non-sporulating strain of Gibberella zeae. Mycologia 1965; 57: 962–966.

32. Gupta AK, Paquet M, Simpson F, Tavakkol A. Terbinafine in the treatment of dermatophyte toenail onychomycosis: a meta-analysis of efficacy for continuous and intermittent regimens. J Eur Acad Dermatol Venereol. 2013; 27: 267–272.

33. Al-Hatmi A M S, Curfs-Breuker I, de Hoog G S, Meis J M, Verweij P E. Antifungal susceptibility testing of Fusarium: a practical approach. J Fungi 2017; 3:19.

34. Rajput C D, Lilani S, Paradeshi K, Deore V S. Localized cutaneous hyalohyphomycosis by Fusarium spp. over a postsurgical scar: response to fluconazole. Ind Dermatol Online J. 2019; 10:307–310.

35. Sun L, Liao K, Wang D. Effect of magnolol and honokiol on adhesion, yeast-hyphal transition, and formation of biofilm by Candida albicans. PLoS ONE 2015; 10: e0117695. https://doi.org/10.1371/journal.pone.0117695 PMID: 25710475

36. Wang Z. Plant-derived antifungal compounds trigger a common transcriptional response. Inf Genet Evol. 2017; 54: 1–3.

37. Wang Z and Shen Y. Antifungal compound honokiol triggers oxidative stress responsive signalling pathway and modulates central carbon metabolism. Mycology 2016; 7: 124–133. https://doi.org/10.1080/21501203.2016.1221862 PMID: 30123624

38. Zhou P, Fu J, Hua H, Liu X. In vitro inhibitory activities of magnolol against Candida spp. Drug Des Develop Ther. 2017; 11: 2653–2661.

39. Denning DW. Echinocandins: a new class of antifungal. J Antimicrob Chemother. 2002; 49: 889–891.

40. Sun L, Liao K, Hang C, Wang D. Honokiol induces reactive oxygen species-mediated apoptosis in Candida albicans through mitochondrial dysfunction. PLoS ONE 2017; 12: e0172228. https://doi.org/10.1371/journal.pone.0172228 PMID: 28192489

41. Zhu X, Zou S, Li Y, Liang Y. Transcriptomic analysis of Saccharomyces cerevisiae upon honokiol treatment. Res Microbiol. 2017; 168: 626–635.

42. Wiederhold NP. The antifungal arsenal: alternative drugs and future targets. Int J Antimicrob Agents 2018; 51: 333–339.